Zai Lab's Q2 2026 Call: Profitability Timelines, ZL-1503 Data Readouts Don't Match

Date of Call: Aug 6, 2026

Financials Results

• Revenue: Net product revenue grew 11% sequentially to $105.8 million

Guidance:

• Expect a return to meaningful year-on-year revenue growth in 2027, driven by new product launches and the potential of key brands.
• Expect operating expenses to remain broadly stable through the remainder of the year.
• Expect U.S. accelerated approval submission for SOZI in 2027, with approval anticipated in 2028.
• Expect to complete enrollment in the dose escalation portion of CL6201's global phase 1 study with initial data expected in the first half of 2027.
• Expect to submit an IND for ZL1311 (T-cell engager targeting mucin 17) by year-end 2026.

Business Commentary:

Pipeline Progress and Global Expansion:

• Xilab is advancing its pipeline with a focus on oncology and immunology, with three registrational programs for SOZI in small cell lung cancer and neuroendocrine carcinoma.
• The company is conducting trials in multiple centers globally and expects to submit its first U.S. regulatory application in 2026, reflecting a strategic move towards becoming a global biopharmaceutical company.

Revenue Growth and Profitability:

• Net product revenue grew by 11% sequentially to $105.8 million, and the business remained commercially profitable.
• This growth was driven by increased demand for its products, including strong performance in the domestic market and the launch of new products.

Atopic Dermatitis and New Product Development:

• The company is developing ZL1503, a long-acting IL-13, IL-31 bispecific antibody for atopic dermatitis, with plans to present first human data later in the year.
• The focus on rapid dosing intervals and potential efficacy in treating atopic dermatitis positions Xilab to address a significant unmet medical need in a large market.

Strategic Partnerships and Collaborations:

• Xilab is collaborating with Amgen and Boehringer Ingelheim to evaluate SOZI in combination with T-cell engagers, aiming to enhance treatment regimens for various cancers.
• These partnerships are part of a broader strategy to leverage external expertise and resources to accelerate the development of innovative therapies.

Financial Stability and Future Investments:

• The company ended the quarter with $717.5 million in cash, providing flexibility to continue investing in high-value programs.
• This financial position allows Xilab to maintain a disciplined capital allocation strategy while supporting the growth of its commercial business and pipeline of innovative medicines.

Sentiment Analysis:

Overall Tone: Positive

• "Xilab has reached an important inflection point in its evolution... We are developing our only next year... We have different stages of development simultaneously at speed and efficiency... We look forward to sharing updates as the program advances... We are confident in a return to meaningful growth..."

Q&A:

• Question from Analyst (UBS): Can you walk us through what you're looking for in the first line small cell study of Zosi plus IO plus or minus chemo?
  Response: Expect to present data from about 60 patients with a doublet combination, aiming for a response rate in the 60-70% range and a clinically meaningful increase in median PFS, with the goal of creating a chemo-sparing regimen.

• Question from Analyst (UBS): How to revisit the profitability goal and how should we think about the differentiation of your IL-13, IL-31 asset versus competitors?
  Response: Profitability will improve over time through operating efficiencies, global program approvals, and disciplined capital allocation. The asset ZL1503 is designed to break the itching inflammation cycle with rapid pruritus reduction, extended dosing intervals, and potential differentiation in the atopic dermatitis market.

• Question from Analyst: For 1503, what is the potential dosing profile and what are early trends on the antibody drug conjugates?
  Response: The dosing regimen is still being determined; a bioequivalency study comparing IV to subcutaneous administration will be conducted, and more dose experiments are needed. The antibody drug conjugate study continues, but no specific early trends were detailed.

• Question from Analyst: How do you envision the China business to evolve in the coming quarters?
  Response: Focus is on stabilizing and solidifying underlying demand for key regional brands, with an eye towards returning to meaningful year-on-year growth in 2027 and preparing for NRDL negotiations.

• Question from Analyst: As your MUC17 T-cell engager approaches the clinic, what aspects of the preclinical profile give you the greatest confidence?
  Response: Confidence is based on the mechanism engineered to have higher efficacy and a CD3 domain designed to silence and reduce cytokine release syndrome, aiming for a product that can be administered in the community.

• Question from Analyst (Goldman): Can you address the question on the combo of OC plus TCE and why it may have value versus a B7H3 combo?
  Response: The combination leverages orthogonal mechanisms (cytotoxic ADC and TCE) for potential synergy, with DLL3 being a more tumor-specific target than B7H3, which may reduce toxicity.

• Question from Ling Han (Goldman): Regarding the ZOSI and TCE combinations, will the RP2D remain at 1.6 mcg, and when will we see data from the Amgen study?
  Response: The doses for SOCI are likely to remain at 1.6 mg/kg; data from the Amgen study is expected in the second half of the year.

Contradiction Point 1

Profitability Timeline Guidance

Guidance shifted from a specific near-term target to a more general, capital allocation-focused outlook.

Company Not Specified - Company Not Specified

2026Q2: Profitability is viewed through capital allocation... Disciplined investment in high-value global programs aims to create long-term value, with global approval in 2028 expected to improve margins further. - Yajing Chen(CFO)

"Given the previous guidance toward profitability by end of 2025, how is the company revisiting this goal and when do you expect investors to see progress?" - Michael Yee (UBS Investment Bank)

2025Q4: Corporate profitability is a clear objective; the company is commercially profitable now. Timing is driven by top-line growth rate and investment levels in global programs. The goal is to balance progress toward profitability with preserving flexibility... - Yajing Chen(CFO)

Contradiction Point 2

ZL-1503 Atopic Dermatitis (AD) Patient Data Timeline

Contradiction on when AD patient data for ZL1503 will be available.

(Company Not Specified) - (Company Not Specified)

2026Q2: The program is ahead of some competitors with data expected in the second half of this year. - Rafael (Xilab)

The company previously guided toward profitability by end of 2025. How to revisit the profitability goal... The second question is on IL-13, IL-31. How should we think about the differentiation of your asset versus competitors. - Kyle Yang (UBS, for Michael Yee)

2026Q1: Healthy volunteer data... is expected by end of 2026, with AD patient data expected in the second half of 2026. - Dr. Rafael Amado

Contradiction Point 3

Frontline SCLC Data Readout Timeline

Contradiction on the expected timing for data from the frontline SCLC study.

(Company Not Specified) - (Company Not Specified)

2026Q2: Expect to present about 60 patients worth of data at ESMO with medium follow-up (8-9 months). - Rafael (Xilab)

What are the key parameters, size, and scope of the first-line small cell study of Zosi plus IO plus/minus chemo, and how will the data be structured? - Kyle Yang (UBS, for Michael Yee)

2026Q1: Data from a phase I study in 1L SCLC is expected in the fall. - Dr. Rafael Amado

Contradiction Point 4

ZOSI (Zosi) Phase III Trial Timeline

Specific enrollment completion target date was provided previously but not reiterated in the latest call.

Company Not Specified - Company Not Specified

2026Q2: Data from the Amgen Phase 1b study... is expected in the second half of the year, though the exact timing will be decided jointly with Amgen. - Rafael (Xilab)

What are the next steps for the ZOSI and DL phase 1/2 trials, and when will Amgen launch the operation? - Michael Yee (UBS Investment Bank)

2025Q4: The global Phase III trial for zoci... Enrollment aims for ~75% completion by end of 2026, with all enrollment to finish by Q1 2027, followed by interim analysis and filing. - Rafael Amado

Contradiction Point 5

ZL-1503 Development Timeline and Data

Contradiction on the stage and expected timeline of first data for the ZL-1503 asset.

(Company Not Specified) - (Company Not Specified)

2026Q2: ZL1503... program is ahead of some competitors with data expected in the second half of this year. - Rafael (Xilab)

How should we think about revisiting the profitability goal by end of 2025, when can investors start expecting progress, and how does the differentiation of your IL-13/IL-31 asset compare to competitors? - Jonathan Chang (Leerink Partners)

2025Q3: A first-in-human study is planned across multiple countries, with first-in-human data expected in 2026. - Rafael Amado(President and Head of Global R&D)